FierceBiotechOriginal article
{"a":[{"_":"BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca","$":{"href":"/biotech/biomarin-bulks-bone-unit-275m-alesta-buyout-challenge-astrazeneca","hreflang":"en"}}]}
Positive
AI Analysis
Summary
BioMarin Pharmaceutical agreed to acquire Alesta Therapeutics for $275 million upfront to expand its bone disease portfolio and compete with AstraZeneca in the rare bone disease market.
Outcome Details
BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront
Importance:7/10
Sentiment:
0.60
M&Aacquisitionbone diseaserare diseasepipeline expansion
Related Companies
Read the original article
Published by FierceBiotech on August 18, 2026 9:15 AM